SPY330.77-3.73 -1.12%
DIA276.49-2.41 -0.87%
IXIC10,793.28-117.00 -1.07%

Stifel Upgrades CymaBay Therapeutics to Buy, Raises Price Target of $8

Stifel analyst Derek Archila upgrades CymaBay Therapeutics (NASDAQ:CBAY) from Hold to Buy and raises the price target from $4 to $8.

Benzinga · 05/12/2020 11:24

Stifel analyst Derek Archila upgrades CymaBay Therapeutics (NASDAQ:CBAY) from Hold to Buy and raises the price target from $4 to $8.